drugset / Trial / NCT00587288

Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma

NCT00587288

Phase 2 Completed 106 enrolled Ception Therapeutics Cephalon · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the effectiveness and safety of reslizumab in the treatment of subjects with poorly controlled asthma.

Timeline

Start
2008-04
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Reslizumab Monoclonal antibody 3 mg/kg Intravenous

Indications